CoreCap Advisors’s Travere Therapeutics TVTX Stock Holding History

CoreCap Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19K	Hold	21	–	–	﹤0.01%	2658
2026 Q1	$624	Hold	21	–	–	﹤0.01%	2615
2025 Q4	$802	Buy	+21	New	+$683	﹤0.01%	2630

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CoreCap Advisors's TVTX Position: Q2 2026 in Review

CoreCap Advisors held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 21 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2658.

CoreCap Advisors first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

CoreCap Advisors held 21 shares of Travere Therapeutics worth $1.19K as of Q2 2026.
CoreCap Advisors left its Travere Therapeutics share count unchanged in Q2 2026.
Travere Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2658 holding.
CoreCap Advisors first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.